Plain-English translation of NCT06698003 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can prevent a rare type of blood cancer called adult T-cell leukemia/lymphoma (ATL) in people who are infected with the HTLV-1 virus. You qualify for this study if you carry the virus and have specific changes in your T-cells (immune cells) that put you at higher risk. The goal is to understand whether this treatment can stop the cancer from ever developing.
Most people infected with HTLV-1 never develop ATL, but some do—and doctors don't yet have a proven way to prevent it in high-risk patients. This medication has shown promise in treating ATL, and researchers want to test whether giving it earlier, to people at high risk, can actually prevent the cancer from forming in the first place.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication at a cancer center. Depending on which group you are assigned to, you will receive either 2 infusions spaced 12 weeks apart, or 4 infusions spaced 6 weeks apart. Throughout the study, you will have regular blood tests and doctor visits to monitor how the treatment is working and to check for any side effects. The study team will follow your health closely to ensure the treatment is safe and effective for you.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States